Robert B Kargbo

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 91

Top Venues

ACS medicinal chemistry letters

Journal of xenobiotics

Journal of the American Chemical Society

ACS omega

Usona Institute

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Usona Institute

United States

Medicinal Chemist :: Medicinal Chemistry

Publications

Robert B Kargbo
Expanding the Chemical Space: New Approach to Cell-Permeable Drugs. ACS medicinal chemistry letters 14 (10) (2023)
Robert B Kargbo
KRAS-Degrading Compounds: A Novel Approach to Treat Cancer by Targeting Both Wild-Type and Mutated KRAS Forms. ACS medicinal chemistry letters 14 (11) (2023)
Robert B Kargbo
Small-Molecule Heterocyclic Compounds: Gq-Biased Agonists for the 5-HT2A Receptor in Neuropsychiatric Treatment. ACS medicinal chemistry letters 14 (11) (2023)
Robert B Kargbo
Microbiome: The Next Frontier in Psychedelic Renaissance. Journal of xenobiotics 13 (3) (2023)
Robert B Kargbo
Microbiome-Gut-Brain Axis Modulation: New Approaches in Treatment of Parkinson's Disease and Amyotrophic Lateral Sclerosis. ACS medicinal chemistry letters 14 (7) (2023)
Robert B Kargbo
Exploring Next-Generation Therapeutics: Morphic Mixtures and Specified Salts for the Treatment of Mental Disorders and CNS Modulation. ACS medicinal chemistry letters 14 (9) (2023)
Robert B Kargbo
Discovery of Potent Deuterated Compounds as Potential KRAS G12D Inhibitors in Cancer Therapy. ACS medicinal chemistry letters 14 (4) (2023)
Robert B Kargbo
Psychedelic-Assisted Neuroplasticity for the Treatment of Mental Health Disorders. ACS medicinal chemistry letters 14 (2) (2023)
Robert B Kargbo
Orally Active Forms of DMT, 5-MeO-DMT, and Long-Acting MDMA for the Treatment of Neuropsychiatric Disorders. ACS medicinal chemistry letters 14 (4) (2023)
Robert B Kargbo
PROTAC: Harnessing Targeted Chimeras for Selective BCL-2 Degradation in Cancer Treatment. ACS medicinal chemistry letters 14 (5) (2023)
Robert B Kargbo
Psychoplastogens: A Novel Therapeutic Approach for Neurological Diseases and Disorders. ACS medicinal chemistry letters 14 (9) (2023)
Robert B Kargbo
Redefining Cancer Therapy: Toward BCL-XL/BCL-2 Dual Inhibitors with Diminished Platelet Toxicity. ACS medicinal chemistry letters 14 (9) (2023)
Robert B Kargbo
Effective Combination Therapies for the Treatment of HER2 Cancer. ACS medicinal chemistry letters 14 (3) (2023)
Robert B Kargbo
PROTAC: Harnessing Targeted Chimeras for Selective BCL-2 Degradation in Cancer Treatment. ACS medicinal chemistry letters 14 (5) (2023)
Robert B Kargbo
Discovery of Selective Aldehyde Dehydrogenase Inhibitors for the Treatment of Cancer. ACS medicinal chemistry letters 14 (2) (2023)
Robert B Kargbo
Unveiling New KRAS G12D Inhibitors: A Promising Approach for Pancreatic Cancer Therapy. ACS medicinal chemistry letters 14 (7) (2023)
Robert B Kargbo
Targeted Degradation of CDK4/6: An Innovative Approach to Overcoming Cancer Drug Resistance. ACS medicinal chemistry letters 14 (9) (2023)
Robert B Kargbo
Tryptamines and Mental Health: Activating the 5-HT Receptor for Therapeutic Potential. ACS medicinal chemistry letters 14 (10) (2023)
Robert B Kargbo
PARP7 Inhibition: A Promising Pathway to Advancements in Cancer Therapy. ACS medicinal chemistry letters 14 (9) (2023)
Robert B Kargbo
Targeting KRAS G12D Mutations: Discovery of Small Molecule Inhibitors for the Potential Treatment of Intractable Cancers. ACS medicinal chemistry letters 14 (8) (2023)
Robert B Kargbo
Development and Utilization of Novel Transglutaminase 2 Inhibitors for Potential Treatment of Autoimmune Disease and Gastrointestinal Disorder. ACS medicinal chemistry letters 14 (11) (2023)
Robert B Kargbo
Discovery of Selective Aldehyde Dehydrogenase Inhibitors for the Treatment of Cancer. ACS medicinal chemistry letters 14 (2) (2023)
Robert B Kargbo
Pioneering Changes in Psychiatry: Biomarkers, Psychedelics, and AI. ACS medicinal chemistry letters 14 (9) (2023)
Robert B Kargbo
Targeted Degradation of KRAS G12D as Potential Therapy in Cancer. ACS medicinal chemistry letters 14 (5) (2023)
Robert B Kargbo
Subhallucinogenic Concentrations of Substituted Phenethylamines as a Novel Therapeutic Approach for Inflammatory and Neurological Disorders. ACS medicinal chemistry letters 14 (7) (2023)
Robert B Kargbo
Psychedelic-Assisted Neuroplasticity for the Treatment of Mental Health Disorders. ACS medicinal chemistry letters 14 (2) (2023)
Robert B Kargbo
PROTAC Targeted Degradation of IRAK-4 as Potential Treatment in Cancer. ACS medicinal chemistry letters 14 (5) (2023)
Robert B Kargbo
Discovery of Selective and Potent KRAS G12D Inhibitors as Potential Therapy in Cancer. ACS medicinal chemistry letters 14 (6) (2023)
Robert B Kargbo
Cyclin-Dependent Kinase Degradation via E3 Ligase Binding for Potential Disease Modulation in Cancer Treatment. ACS medicinal chemistry letters 14 (8) (2023)
Robert B Kargbo
Microbiome-Gut-Brain Axis Modulation: New Approaches in Treatment of Neuropsychological and Gastrointestinal Functional Disorders. ACS medicinal chemistry letters 14 (6) (2023)
Robert B Kargbo
PROTAC Targeted Degradation of IRAK-4 as Potential Treatment in Cancer. ACS medicinal chemistry letters 14 (5) (2023)
Robert B Kargbo
Unraveling Psychedelic Responses: Targeted Protein Degradation and Genetic Diversity. ACS medicinal chemistry letters 14 (8) (2023)
Robert B Kargbo
New Horizons in Cancer Treatment: A Closer Look at Novel PI3Kα Inhibitors. ACS medicinal chemistry letters 14 (9) (2023)
Robert B Kargbo
Targeted Degradation of KRAS G12D as Potential Therapy in Cancer. ACS medicinal chemistry letters 14 (5) (2023)
Robert B Kargbo
Neurosteroids and Postpartum Depression: The Mechanism, Efficacy, and Approval of Brexanolone and Zurzuvae. ACS medicinal chemistry letters 14 (10) (2023)
Robert B Kargbo
Targeting the "Undruggable" Driver Protein, KRAS G12D , as Potential Therapy in Prostate Cancer. ACS medicinal chemistry letters 14 (4) (2023)
Robert B Kargbo
The Synergistic Effects of 5-HT2A and TRP Agonism/Antagonism in Reducing Inflammation for Enhanced Mental and Physical Health. ACS medicinal chemistry letters 14 (8) (2023)
Robert B Kargbo
Potent and Selective BCL-XL Inhibitors and PROTAC Compounds as Potential Cancer Treatment and Immunotherapy. ACS medicinal chemistry letters 14 (6) (2023)
Robert B Kargbo
Application of Rapidly Accelerating Fibrosarcoma Protein Degraders in Drug Discovery. ACS medicinal chemistry letters 13 (6) (2022)
Robert B Kargbo
Therapeutic and Effective CURE-PRO Molecules for E3 Ligase-Mediated Targeted Protein Degradation. ACS medicinal chemistry letters 13 (8) (2022)
Robert B Kargbo
Restoration of Motor Function Post-Neurological Injury Using Serotonergic Agonist. ACS medicinal chemistry letters 13 (9) (2022)
Robert B Kargbo
MDMA and Their Analogs as Therapeutics for Mental Disorder and Response Predictor. ACS medicinal chemistry letters 13 (10) (2022)
Robert B Kargbo
Application of Degradation of Cyclic-AMP Response Element Binding Protein for the Potential Treatment of Cancer. ACS medicinal chemistry letters 13 (8) (2022)
Robert B Kargbo
Potent PROTACs Targeting EGFR Mutants in Drug Discovery. ACS medicinal chemistry letters 13 (12) (2022)
Robert B Kargbo
Application of Deuterated N , N -Dimethyltryptamine in the Potential Treatment of Psychiatric and Neurological Disorders. ACS medicinal chemistry letters 13 (9) (2022)
Robert B Kargbo
SARS-CoV-2: Novel Therapeutic Approaches for Diagnosis and Treatment. ACS medicinal chemistry letters 13 (7) (2022)
Robert B Kargbo
Emerging Proteolysis Targeting Antibodies (PROTABs) for Application in Cancer Therapy. ACS medicinal chemistry letters 13 (12) (2022)
Robert B Kargbo
Potential Treatment for Obsessive-Compulsive Disorder. ACS medicinal chemistry letters 13 (10) (2022)
Robert B Kargbo, Alexander M Sherwood, Poncho Meisenheimer, Kelsey Lenoch, Solomon Abebe
Psilocybin: Characterization of the Metastable Zone Width (MSZW), Control of Anhydrous Polymorphs, and Particle Size Distribution (PSD). ACS omega 7 (6) (2022)
Robert B Kargbo
ALK Inhibitors for Treating Cancer, Blood, and Kidney Diseases. ACS medicinal chemistry letters 13 (10) (2022)
Robert B Kargbo
Targeted Degradation of Androgen Receptor for the Potential Treatment of Prostate Cancer. ACS medicinal chemistry letters 13 (10) (2022)
Robert B Kargbo
Potential Therapeutic Transdermal Psychoactive Drug Delivery Technology. ACS medicinal chemistry letters 13 (12) (2022)
Robert B Kargbo
Discovery of Potent PROTACs for the Potential Treatment of Leukemia. ACS medicinal chemistry letters 13 (12) (2022)
Robert B Kargbo
Potential Therapeutic Transdermal Psychoactive Drug Delivery Technology. ACS medicinal chemistry letters 13 (12) (2022)
Robert B Kargbo
Selective Serotonin Receptor Modulators for Use in the Treatment of Psychological Disorders. ACS medicinal chemistry letters 13 (4) (2022)
Robert B Kargbo
5-HT Receptor Modulators for Therapeutic Use in the Treatment of Obsessive-Compulsive Disorder and Other Psychological Disorders. ACS medicinal chemistry letters 13 (5) (2022)
Robert B Kargbo
Discovery of Potent PROTACs for the Potential Treatment of Leukemia. ACS medicinal chemistry letters 13 (12) (2022)
Robert B Kargbo
Small-Molecule Inhibitor of the Oncogenic KRAS G12C Mutant for the Treatment of Currently Incurable Cancer. ACS medicinal chemistry letters 13 (5) (2022)
Robert B Kargbo
3-Pyrrolidine-indole Derivatives as 5-HT2-Selective Receptor Modulators for the Potential Treatment of Mental Disorders. ACS medicinal chemistry letters 13 (5) (2022)
Robert B Kargbo
Recent Discovery of PARP7 Inhibitors as Anticancer Agents. ACS medicinal chemistry letters 13 (11) (2022)
Robert B Kargbo
Emerging Proteolysis Targeting Antibodies (PROTABs) for Application in Cancer Therapy. ACS medicinal chemistry letters 13 (12) (2022)
Robert B Kargbo
Improved Metabolically Stable 5-HT Receptor Modulators and the Development of New Antidepressants. ACS medicinal chemistry letters 13 (4) (2022)
Robert B Kargbo
Ibogaine and Their Analogs as Therapeutics for Neurological and Psychiatric Disorders. ACS medicinal chemistry letters 13 (6) (2022)
Robert B Kargbo
Selective Cyclin-Dependent Kinase Inhibitors and Their Application in Cancer Therapy. ACS medicinal chemistry letters 13 (10) (2022)
Robert B Kargbo
Application of Compositions Comprising a KRAS G12C Inhibitor and an EGFR Inhibitor for the Potential Treatment of Cancer. ACS medicinal chemistry letters 13 (9) (2022)
Robert B Kargbo
KRAS Inhibitors and Target Engagement Technology: From Undruggable to Druggable Targets in Cancer Therapeutics. ACS medicinal chemistry letters 13 (5) (2022)
Robert B Kargbo
Long-Awaited Small-Molecule Drug Candidate for Drugging the Next Undruggable KRAS G12D Mutant in Cancer Therapy. ACS medicinal chemistry letters 13 (5) (2022)
Robert B Kargbo
Potent PROTACs Targeting EGFR Mutants in Drug Discovery. ACS medicinal chemistry letters 13 (12) (2022)
Robert B Kargbo
Targeting KRAS Mutant Protein Inhibitor for Potential Treatment in Cancer. ACS medicinal chemistry letters 12 (11) (2021)
Robert B Kargbo
Improved 5-HT2 Selective Receptor Modulators for the Treatment of Psychological Disorders. ACS medicinal chemistry letters 12 (12) (2021)
Robert B Kargbo
5-MeO-DMT: Potential Use of Psychedelic-Induced Experiences in the Treatment of Psychological Disorders. ACS medicinal chemistry letters 12 (11) (2021)
Robert B Kargbo
Protein Degradation Inducers of Androgen Receptor by Conjugation of Antagonists Androgen Receptor and E3 Ligase Ligand. ACS medicinal chemistry letters 12 (10) (2021)
Robert B Kargbo
Improved Synthesis of New FDA-Approved Treatment for KRAS G12C Mutation in Non-small Cell Lung Cancer. ACS medicinal chemistry letters 12 (8) (2021)
Robert B Kargbo
PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase as a Therapeutic Strategy for Cancer. ACS medicinal chemistry letters 12 (5) (2021)
Robert B Kargbo
Discovery of Spirocyclic Androgen Receptor Protein Degraders for the Treatment of Prostate Cancer. ACS medicinal chemistry letters 12 (11) (2021)
Robert B Kargbo
Psychedelic Therapeutic: Potential Treatment for Headache Disorders. ACS medicinal chemistry letters 12 (10) (2021)
Robert B Kargbo
Psilocin Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders. ACS medicinal chemistry letters 12 (10) (2021)
Robert B Kargbo
RIBOTACs: Small Molecules Selectively Destroy Cancer-Associated RNA. ACS medicinal chemistry letters 12 (12) (2021)
Robert B Kargbo
Therapeutic Modulation of NLRP3 for Treatment of Cancer, Alzheimer's Disease, and Trauma. ACS medicinal chemistry letters 12 (7) (2021)
Robert B Kargbo
Modulation of KRAS Mutant by Inhibiting PLK1 Kinase in Cancer Therapeutics. ACS medicinal chemistry letters 12 (10) (2021)
Robert B Kargbo
Targeting IRAK1 for Degradation with PROTACs. ACS medicinal chemistry letters 12 (6) (2021)
Robert B Kargbo
Dual Inhibition of KRAS G12C and G12D Mutants as a Potential Treatment in Cancer Therapy. ACS medicinal chemistry letters 12 (10) (2021)
Robert B Kargbo
The Psychedelic Renaissance: Addressing Potential Adverse Effects in a Therapeutic Setting. ACS medicinal chemistry letters 12 (12) (2021)
Robert B Kargbo
Small Molecule Inhibitors of KRAS Mutant as a Therapeutic Strategy for the Treatment of Cancer. ACS medicinal chemistry letters 12 (8) (2021)
Robert B Kargbo
Targeting KRAS G12D Mutant for the Potential Treatment of Pancreatic Cancer. ACS medicinal chemistry letters 12 (11) (2021)
Robert B Kargbo
Small Molecule Inhibitors of KRAS G12C Mutant. ACS medicinal chemistry letters 12 (8) (2021)
Robert B Kargbo
Modulating Androgen Receptor in the Therapeutic Intervention for Prostate Cancer and Kennedy's Disease. ACS medicinal chemistry letters 12 (5) (2021)
Robert B Kargbo
KRAS Mutant Combination Therapy for the Effective Treatment of Cancer. ACS medicinal chemistry letters 12 (10) (2021)
Robert B Kargbo
PROTAC-Mediated Degradation of Janus Kinase as a Therapeutic Strategy for Cancer and Rheumatoid Arthritis. ACS medicinal chemistry letters 12 (6) (2021)
Robert B Kargbo
Targeting the KRAS G12D Mutant as Potential Therapy in Cancer. ACS medicinal chemistry letters 12 (8) (2021)
Stefan Kraft, Kristen Ryan, Robert B Kargbo
Recent Advances in Asymmetric Hydrogenation of Tetrasubstituted Olefins. Journal of the American Chemical Society 139 (34) (2017)

Robert B Kargbo.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Robert B Kargbo